Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Ramirez

Showing results (161-170 of 177) with videos related to

Pageof 18
Sort By:
Infectious Diseases and Therapy|March 23, 2024
Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019Aleksandra Polkowska-Kramek, Elizabeth Begier, Robin Bruyndonckx, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2018
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung CancerNiki Karachaliou, Jillian Wilhelmina Paulina Bracht, Manuel Fernandez Bruno, et al.
Thorax|November 26, 2018
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM stagingElena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2009
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patientsEnric Carcereny, Jose Luis Ramirez, Maria Sanchez-Ronco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2010
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patientsFernanda Salazar, Miguel Angel Molina, Maria Sanchez-Ronco, et al.
Oncotarget|October 21, 2016
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinomaLu Chen, Courtney A Kurtyka, Eric A Welsh, et al.
Plos One|March 4, 2014
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trialSusana Benlloch, Maria Luisa Botero, Jordi Beltran-Alamillo, et al.
Acta Biomaterialia|March 12, 2019
Bone extracts immunomodulate and enhance the regenerative performance of dicalcium phosphates bioceramicsAlaa Mansour, Lina Abu-Nada, Haider Al-Waeli, et al.
Journal of the National Cancer Institute|April 13, 2011
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapyXifeng Wu, Yuanqing Ye, Rafael Rosell, et al.
Journal of Neuro-Oncology|February 6, 2016
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trialCarmen Balana, Ramon De Las Penas, Juan Manuel Sepúlveda, et al.
Pageof 18

Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Infectious Diseases and Therapy|March 23, 2024
Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019Aleksandra Polkowska-Kramek, Elizabeth Begier, Robin Bruyndonckx, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2018
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung CancerNiki Karachaliou, Jillian Wilhelmina Paulina Bracht, Manuel Fernandez Bruno, et al.
Thorax|November 26, 2018
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM stagingElena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2009
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patientsEnric Carcereny, Jose Luis Ramirez, Maria Sanchez-Ronco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2010
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patientsFernanda Salazar, Miguel Angel Molina, Maria Sanchez-Ronco, et al.
Oncotarget|October 21, 2016
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinomaLu Chen, Courtney A Kurtyka, Eric A Welsh, et al.
Plos One|March 4, 2014
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trialSusana Benlloch, Maria Luisa Botero, Jordi Beltran-Alamillo, et al.
Acta Biomaterialia|March 12, 2019
Bone extracts immunomodulate and enhance the regenerative performance of dicalcium phosphates bioceramicsAlaa Mansour, Lina Abu-Nada, Haider Al-Waeli, et al.
Journal of the National Cancer Institute|April 13, 2011
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapyXifeng Wu, Yuanqing Ye, Rafael Rosell, et al.
Journal of Neuro-Oncology|February 6, 2016
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trialCarmen Balana, Ramon De Las Penas, Juan Manuel Sepúlveda, et al.
Pageof 18